First Major Technological Breakthrough in HA Dermal Fillers in a Decade
SYMATESE reaches a milestone in its history and announces FDA Approval of EVOLYSSE™ FORM and EVOLYSSE™ SMOOTH Injectable Hyaluronic Acid Gels.
SYMATESE achieves a major breakthrough with EVOLUS, getting the FDA approval of EVOLYSSE™ FORM and EVOLYSSE™ SMOOTH, next-generation hyaluronic acid injectable gels powered by cutting-edge COLD-X™ TECHNOLOGY. Designed for long-lasting, natural-looking results, these innovations will be exclusively launched in the U.S. by Evolus in Q2 2025. This milestone marks SYMATESE’s bold entry into the $1.6 billion U.S. dermal filler market and accelerates its global expansion, with upcoming launches in Europe, China, and Brazil.
